CutisPharma Acquires Silvergate Pharmaceuticals and Rebrands as Azurity Pharmaceuticals
June 12, 2019
CutisPharma, majority-backed by NovaQuest Private Equity (now QHP Capital), has acquired Silvergate Pharmaceuticals and the combined company will be rebranded as Azurity Pharmaceuticals. The transaction consolidates complementary specialty pharmaceutical portfolios and capabilities—combining CutisPharma’s recently launched products with Silvergate’s SG-05 pipeline submission—and is supported by debt financing arranged by Goldman Sachs Specialty Lending Group.
- Targets
- Silvergate Pharmaceuticals, Inc.
- Industry
- Pharmaceuticals
- Location
- Colorado, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.